IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures

IM Therapeutics is a clinical stage company developing personalized therapies for autoimmune disease. On October 9th, they announced that they have raised $10 million in Series A financing to advance their novel HLA-targeted discovery platform and develop their lead drug candidate in type 1 diabetes! The funding was co-led by the JDRF T1D Fund and Morningside Ventures, with participation from the Colorado University Healthcare Innovation Fund. Their research showed that blocking action of certain human leukocyte antigen (HLA) gene variants known to be high risk factors blocks the corresponding autoimmune response. As the first such personalized therapy approach in autoimmunity, the Company

Welcome IM Therapeutics to the C2I Family!

We would love to extend our warm welcome to IM Therapeutics! IM Therapeutics is redefining autoimmunity and transforming lives by building novel personalized medicines for autoimmune diseases with a first-of-its-kind targeted drug design and patient-centered approach. Their novel therapies specifically block the action of HLA proteins known to be involved in the triggering of an autoimmune response. To learn more, visit their website:

Featured Posts
Recent Posts
Search By Tags

© 2019 by CreaGen Inc. 

299 Washington St

Woburn, MA 01801 

Tel: 781.938.1122

Fax: 781.938.1123

  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey YouTube Icon
  • Grey Facebook Icon

Business Accelerator | CreaGen C2I | Life Science | Lease Lab Space | Biotech